Suchergebnisse - "Amiot, Aurélien"

PubPharm (16)

1

Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis : A Multicentre Cohort Study from the GETAID

enthalten in: Journal of Crohn's & colitis | 2024

von Uzzan, M. | Nachury, M. | Nuzzo, A. | +54

2

Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease : Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

enthalten in: Journal of Crohn's & colitis | 2024

von Ten Bokkel Huinink, S. | Thomassen, D. | Steyerberg, E. | +17

3

Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent

enthalten in: Alimentary pharmacology & therapeutics | 2023

von Buisson, A. | Nachury, M. | Guilmoteau, T. | +9

CommentIn: Aliment Pharmacol Ther. 2023 Mar;57(6):733-734. - PMID 36821750

4

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis : a GETAID multicentre cohort study

enthalten in: Scandinavian journal of gastroenterology | 2022

von Meyer, A. | Fumery, M. | Peyrin-Biroulet, L. | +22

5

Biologic Therapy for Budesonide-refractory, -dependent or -intolerant Microscopic Colitis : a Multicentre Cohort Study from the GETAID

enthalten in: Journal of Crohn's & colitis | 2022

von Boivineau, G. | Zallot, C. | Zerbib, F. | +6

6

Paradoxical reactions and biologic agents : a French cohort study of 9303 patients

enthalten in: The British journal of dermatology | 2022

von Bataille, P. | Layese, R. | Claudepierre, P. | +5

CommentIn: Br J Dermatol. 2022 Nov;187(5):638. - PMID 36104827

7

Prevalence of anti-TNF contraindications in Crohn's disease : A cross-sectional survey from the GETAID

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Amiot, A. | Seksik, P. | Reimund, J. | +80

8

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease : Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Pauwels, R. | van der Woude, C. | Nieboer, D. | +55

CommentIn: Clin Gastroenterol Hepatol. 2022 Aug;20(8):1668-1670. - PMID 34058414

9

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease

enthalten in: Inflammatory bowel diseases | 2022

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

10

Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis : A GETAID cohort

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Uzzan, M. | Bresteau, C. | Laharie, D. | +49

CommentIn: Aliment Pharmacol Ther. 2021 Aug;54(3):341-342. - PMID 34236096